TREE NEWS update: Experts said there is no confirmed causal link between GLP-1 weight-loss injections such as semaglutide and tirzepatide and vision damage or blindness, calling reported cases rare and isolated. The response came after social media users raised questions over whether the drugs can harm eyesight. The experts said occasional rare cases have been noted but a causal relationship has not been established.
Experts Say GLP-1 Weight-Loss Injections Not Confirmed to Cause Vision Loss
The significance here lies less in the clinical finding than in the information dynamics: a social-media-driven scare is being met with a cautious, evidence-based response emphasizing that rare reported cases do not establish causation. This matters for the credibility of safety discourse around a drug class that has moved rapidly from clinical settings into mainstream use. The open question is whether the absence of a confirmed link will quiet the online concern or whether isolated cases keep resurfacing as anecdote outrunning evidence.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.